Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction

Mayo Clinic Proceedings

Volumn 81, Issue 9, 2006, Pages 1207-1214

  Pittock, Sean J ^a   Yoshikawa, Hiroaki ^a,c   Ahlskog, J Eric ^a   Tisch, Stephen H ^a,d   Benarroch, Eduardo E ^a   Kryzer, Thomas J ^a   Lennon, Vanda A ^a,b  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c KANAZAWA UNIVERSITY   (Japan)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISONE; THYROID ANTIBODY;

ADULT; AFRICAN AMERICAN; AGED; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; BRAIN STEM INJURY; CEREBELLAR ATAXIA; ENZYME ANALYSIS; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; ONSET AGE; PLASMAPHERESIS; RADIOIMMUNOPRECIPITATION; RETROSPECTIVE STUDY; SEIZURE; SPINAL CORD DISEASE; STATISTICAL ANALYSIS; STIFF MAN SYNDROME;

EID: 33748146129     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.9.1207     Document Type: Article

References (41)

1. Erlander MG, Tobin AJ. The structural and functional heterogeneity of glutamic acid decarboxylase: a review. Neurochem Res. 1991;16:215-226.
2. Mugnaini E, Oertel WH. An atlas of the distribution of GABAergic neurons and terminals in the rat central nervous system as revealed by GAD immunohistochemistry. In: Björklund A, Hökfelt T, eds. Handbook of Chemical Neuroanatomy. Vol. 4: GABA and Neuropeptides in the Central Nervous System, Part 1. Amsterdam, Netherlands: Elsevier; 1985:436-608.
3. Reetz A, Solimena M, Matteoli M, Folli F, Takei K, De Camilli P. GABA and pancreatic beta-cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggests their role in GABA storage and secretion. EMBO J. 1991;10:1275-1284.
4. Persson H, Pelto-Huikko M, Metsis M, et al. Expression of the neurotransmitter-synthesizing enzyme glutamic acid decarboxylase in male germ cells. Mol Cell Biol. 1990;10:4701-4711.
5. Erdo SL, Joo F, Wolff JR. Immunohistochemical localization of glutamate decarboxylase in the rat oviduct and ovary: further evidence for non-neural GABA systems. Cell Tissue Res. 1989;255:431-434.
6. Walikonis JE, Lennon VA. Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. Mayo Clin Proc. 1998;73:1161-1166.
7. Solimena M, Folli F, Denis-Donini S, et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med. 1988;318:1012-1020.
8. Barker RA, Revesz T, Thom M, Marsden CD, Brown P. Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry. 1998;65:633-640.
9. Brown P, Marsden CD. The stiff man and stiff man plus syndromes. J Neurol. 1999;246:648-652.
10. Burn DJ, Ball J, Lees AJ, Behan PO, Morgan-Hughes JA. A case of progressive encephalomyelitis with rigidity and positive antiglutamic acid decarboxylase antibodies [published correction appears in J Neurol Neurosurg Psychiatry. 1991;54:1032]. J Neurol Neurosurg Psychiatry. 1991;54:449-451.
11. Meinck HM, Faber L, Morgenthaler N, et al. Antibodies against glutamic acid decarboxylase: prevalence in neurological diseases. J Neurol Neurosurg Psychiatry. 2001;71:100-103.
12. Saiz A, Arpa J, Sagasta A, et al. Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity. Neurology. 1997;49:1026-1030.
13. Honnorat J, Saiz A, Giometto B, et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol. 2001;58:225-230.
14. Takenoshita H, Shizuka-Ikeda M, Mitoma H, et al. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia. J Neurol Neurosurg Psychiatry. 2001;70:386-389.
15. Abele M, Weller M, Mescheriakov S, Burk K, Dichgans J, Klockgether T. Cerebellar ataxia with glutamic acid decarboxylase autoantibodies. Neurology. 1999;52:857-859.
16. Peltola J, Kulmala P, Isojarvi J, et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology. 2000;55:46-50.
17. Honnorat J, Trouillas P, Thivolet C, Aguera M, Belin MF. Autoantibodies to glutamate decarboxylase in a patient with cerebellar cortical atrophy, peripheral neuropathy, and slow eye movements. Arch Neurol. 1995;52:462-468.
18. Meinck HM, Thompson PD. Stiff man syndrome and related conditions. Mov Disord. 2002;17:853-866.
19. Khasani S, Becker K, Meinck HM. Hyperekplexia and stiff-man syndrome: abnormal brainstem reflexes suggest a physiological relationship. J Neurol Neurosurg Psychiatry. 2004;75:1265-1269.
20. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49:146-154.
21. Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol. 2001;50:301-311.
22. Griesmann GE, Kryzer TJ, Lennon VA. Autoantibody profiles of myasthenia gravis and Lambert-Eaton myasthenic syndrome. In: Rose NR, Hamilton RG, Detrick B, eds. Manual of Clinical and Laboratory Immunology. 6th ed. Washington, DC: ASM Press; 2002:1005-1012.
23. Vernino S, Kryzer TJ, Lennon VA. Autoimmune autonomic neuropathy and neuromuscular hyperexcitability disorders. In: Rose NR, Hamilton RG, Detrick B, eds. Manual of Clinical and Laboratory Immunology. 6th ed. Washington, DC: ASM Press; 2002:1013-1017.
24. Cikes N, Momoi MY, Williams CL, et al. Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma and recipients of D-penicillamine and allogeneic bone marrow. Mayo Clin Proc. 1988;63:474-481.
25. Rankin J. Cerebral vascular accidents in patients over the age of 60, II: prognosis. Scott Med J. 1957;2:200-215.
26. Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke. 1988;19:1497-1500.
27. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
28. Meinck HM, Ricker K, Hulser PJ, Schmid E, Peiffer J, Solimena M. Stiff-man syndrome: clinical and laboratory findings in eight patients. J Neurol. 1994;241:157-166.
29. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183-1197.
30. Reveille JD, Moulds JM, Ahn C, et al, LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups, I: the effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis Rheum. 1998;41:1161-1172.
31. Wingerchuk DM. Neuromyelitis optica: current concepts. Front Biosci. 2004;9:834-840.
32. Phillips LH II, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology. 1992;42:1888-1893.
33. Andrews PI, Massey JM, Howard JF Jr, Sanders DB. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology. 1994;44:1208-1214.
34. Robbins JM, Vaccarino V, Zhang H, Kasl SV. Excess type 2 diabetes in African-American women and men aged 40-74 and socioeconomic status: evidence from the Third National Health and Nutrition Examination Survey. J Epidemiol Community Health. 2000;54:839-845.
35. Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res. 2004;10:7270-7275.
36. Amato AA, Cornman EW, Kissel JT. Treatment of stiff-man syndrome with intravenous immunoglobulin. Neurology. 1994;44:1652-1654.
37. Barker RA, Marsden CD. Successful treatment of stiff man syndrome with intravenous immunoglobulin [letter]. J Neurol Neurosurg Psychiatry. 1997;62:426-427.
38. Vicari AM, Folli F, Pozza G, et al. Plasmapheresis in the treatment of stiff-man syndrome [letter]. N Engl J Med. 1989;320:1499.
39. Piccolo G, Cosi V, Zandrini C, Moglia A. Steroid-responsive and dependent stiff-man syndrome: a clinical and electrophysiological study of two cases. Ital J Neurol Sci. 1988;9:559-566.
40. Lauria G, Pareyson D, Pitzolu MG, Bazzigaluppi E. Excellent response to steroid treatment in anti-GAD cerebellar ataxia. Lancet Neurol. 2003;2:634-635.
41. Vianello M, Tavolato B, Armani M, Giometto B. Cerebellar ataxia associated with anti-glutamic acid decarboxylase autoantibodies. Cerebellum. 2003;2:77-79.